skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Topotecan in the treatment of relapsed small cell lung cancer

Review

(6313) Views  (1077) Full article downloads

Authors: Elisabeth Quoix

Published Date December 2008 Volume 2008:1 Pages 79 - 86
DOI: http://dx.doi.org/10.2147/OTT.S3689

Elisabeth Quoix

Service de Pneumologie, Hôpitaux Universitaires, Strasbourg, France

Abstract: Small cell lung cancer (SCLC) represents about 15% to 20% of all lung cancers. Chemotherapy is the cornerstone of the treatment, cisplatin–etoposide combination being the most used combination as first-line therapy. Despite high initial chemosensitivity, most SCLC patients will experience relapse sooner or later. Unfortunately, second-line chemotherapy does not result in a high response rate like first-line therapy, most patients having developed wide chemoresistance. This chemoresistance is far more important in refractory patients, ie, those who never responded to first-line therapy or who relapsed within 3 months after the end of chemotherapy, than in sensitive patients, ie, those who relapse more than 3 months after the end of chemotherapy. Topotecan, a topoisomerase I inhibitor, is the most studied drug in this second-line setting and has proved its efficacy as a single agent and in combination. A phase III trial comparing oral topotecan to best supportive care (BSC) in relapsed SCLC demonstrated a significant survival benefit as well as a better quality of life. Although the usual schedule is 1.5 mg/m2, days 1–5 intravenously, it is not convenient for patients with relapsed SCLC, especially those who are refractory because of their short survival expectation. Oral topotecan is of similar efficacy and much more convenient with limited stay in a treatment unit and has a comparable toxicity profile for these patients with short expected survival. Combination of topotecan with platinum salts or taxanes does not seem to improve further the outcome of the patients and thus single-agent therapy with topotecan is the standard treatment for relapsed SCLC.

Keywords: topotecan, small cell lung cancer, chemoresistance








Readers of this article also read:

Herpes zoster in the T1 dermatome presenting with Horner’s syndrome, radicular weakness, and postherpetic neuralgia
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Critical appraisal of the role of glucosamine and chondroitin in the management of osteoarthritis of the knee
Ego mechanisms of defense are associated with patients’ preference of treatment modality independent of psychological distress in end-stage renal disease
Can a gentamicin-specific chart reduce neonatal medication errors?
Nephroprotective action of glycosaminoglycans: why the pharmacological properties of sulodexide might be reconsidered
Dashboards in neonatology
Epigenomics in cancer management
Intercellular cancer collisions generate an ejected crystal comet tail effect with fractal interface embryoid body reassembly transformation
Phenotype characterization of embryoid body structures generated by a crystal comet effect tail in an intercellular cancer collision scenario